Could the Novel Oral Anticoagulants Be Used for Coronary Artery Aneurysm?

Quanxiang Yan; Libing Ning; Yu Jian; Wencong Yang; Qinghua Yuan; Zhimin Du

doi:10.1155/2020/5073814

Could the Novel Oral Anticoagulants Be Used for Coronary Artery Aneurysm?

Case Rep Med. 2020 Apr 25:2020:5073814. doi: 10.1155/2020/5073814. eCollection 2020.

Authors

Quanxiang Yan¹, Libing Ning¹, Yu Jian², Wencong Yang¹, Qinghua Yuan¹, Zhimin Du²

Affiliations

¹ Cardiovasology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China.
² Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

Abstract

Coronary artery aneurysms (CAAs) are uncommon in coronary angiography, and left main coronary artery aneurysms are rare. There is no consensus for the treatment of CAAs. A young patient with left coronary artery aneurysm diagnosed by coronary angiography and with recurrent acute myocardial infarction was treated with rivaroxaban and aspirin. The patient had no angina for 6 months. Novel oral anticoagulants combined with antiplatelet agents may be appropriate for the treatment of CAAs.

Publication types

Case Reports